The Cheeky Study
Cabenuva is a long-acting injectable HIV medication given once per month via intramuscular injection. Cabenuva is a combination of two HIV medications: cabotegravir and rilpivirine. It is FDA approved for people living with HIV who are stable on a HIV treatment regimen and have an undetectable viral load.
The Cheeky Study is a research study administered by Bridge HIV in partnership with Lyon-Martin Community Health Services with the aim of increasing access to Cabenuva for Transfeminine people. The study is for Transgender Women and Transfeminine Non-Binary People who are HIV+, over the age of 18, and want to try Cabenuva.
If you are interested in joining The Cheeky Study or The Beyond Study, contact Lyon-Martin’s
Positive Care Coordinator, Bo Hwang, at (415) 213-1919 or bhwang@lyon-martin.org.
The Beyond Study
Apretude is the first and only long-acting injectable HIV prevention medication (PrEP) given once every other month via intramuscular injection. Apretude is a brand name version of extended release cabotegravir. It is FDA approved for people who are HIV negative and want to reduce their risk of contracting HIV.
The Beyond Study is a research study administered by Bridge HIV in partnership with Lyon-Martin Community Health Services with the aim of increasing access to Apretude for Transgender and Non-Binary people. The study is for Transgender and Non-Binary People who are HIV negative, over the age of 18, and want to try Apretude to reduce the risk of contracting HIV.